Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages

Summary

Dipyrone is suggested to inhibit the platelet aggregation comparable to th effect of traditional analgetic substances like Ibuprofen. To verify this hypothesis the investigators conducted the study in comparing patients undergoing traumatologic, visceral or plastic surgical procedures. The investigators randomized them to four groups receiving common analgetic doses of either dipyrone, acetaminophen (paracetamol) or valdecoxib/parecoxib. The investigators took blood samples before initiation of the study drug, 1h, 4hs and 24hs after first intake. The investigators compared the aggregation via aggregometry of platelet rich plasma.

Conditions

• Platelet Aggregation

Interventions

DRUG

dipyrone

Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward

DRUG

Ibuprofen

Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day

DRUG

Acetaminophen

Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day

DRUG

Acetaminophen

Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day

DRUG

Parecoxib/Valdecoxib

40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day

OTHER

Blood samples

Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake

Sponsors & Collaborators

• Pfizer

  collaborator INDUSTRY

• Ruhr University of Bochum

  lead OTHER

Principal Investigators

• Matthias Schmauss, MD · research associate of the Ruhr University Bochum

• Christoph Maier, Professor · Leader of the Department for Pain Medicine of the University Hospital Bergmannsheil Bochum

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-02-29

Primary Completion

2004-12-31

Completion

2004-12-31

Countries

• Germany

Study Locations